The late-stage clinical company received a notice in January from the Nasdaq that it was not in compliance with the exchange's $1 minimum closing bid price requirement and could be subject to delisting if it did not regain compliance by July 25.
Sesen said in a regulatory filing Friday that it will no longer seek shareholder approval for its proposal to effect a reverse stock split at a ratio in the range of 1-to-5 to 1-to-10 and a proportionate reduction in the number of its authorized common shares.
The company said it was confident that it could maximize shareholder value without effecting a reverse stock split at this time and that it will weigh its options to regain compliance with Nasdaq's minimum bid price.
Sesen shares were up 31% in recent trading.
Price: 0.77, Change: +0.18, Percent Change: +30.70
|Evolv Technologies Q2 Adjusted Loss Narrows, Revenue...|
|--Stifel Nicolaus Adjusts Price Target for Bausch He...|
|Research Alert: CFRA Maintains Hold Rating On Shares...|
|--Stifel Nicolaus Adjusts Price Target for LiveVox H...|
|ZimVie Q2 Adjusted EPS, Sales Drop; Company Lowers 2...|